SPHERES

PickNik Robotics Secures Two New NASA SBIR Contracts for Advancing Autonomous Robotic Systems

Retrieved on: 
Thursday, June 8, 2023
Maintenance, Robonaut, SBIR, SPHERES, NASA, Motion, Robotics, Laboratory, Artemis, Recovery, OSAM, Computer data storage, Astrobee

BOULDER, Colo., June 8, 2023 /PRNewswire/ -- PickNik Robotics , a leading provider of advanced robotic solutions, is pleased to announce its success in securing two Small Business Innovation Research (SBIR) contracts with NASA.

Key Points: 
  • BOULDER, Colo., June 8, 2023 /PRNewswire/ -- PickNik Robotics , a leading provider of advanced robotic solutions, is pleased to announce its success in securing two Small Business Innovation Research (SBIR) contracts with NASA.
  • These prestigious contracts highlight PickNik Robotics' continued expertise in developing cutting-edge technologies for autonomous robotic manipulation, utilization, and maintenance, as well as integrated mission planning and execution for space operations .
  • With NASA's increasing need for highly autonomous robotic systems to maintain critical spaceflight hardware, PickNik Robotics is pioneering a novel fault detection and reporting system.
  • PickNik's CEO, Dr. Dave Coleman, remarked "We are pushing the boundaries of autonomous robotic systems in order to revolutionize space operations.

The SPHERES Registry for NMOSD Patients Launches Precision Medicine Program

Retrieved on: 
Thursday, May 4, 2023
David Geffen School of Medicine at UCLA, Registry, NMO, Spinal cord, Personalized medicine, Quality of life, Research, Neuromyelitis optica spectrum disorder, Brain, Experiment, MOGAD, Paralysis, Synergy, SPHERES, Patient, Collection, Data, Paratriathlon, UCLA, Phenotype, Disease, Autoimmunity, Safety, Inflammation, Pharmaceutical industry, Vaccine, Medicine, NMOSD

SPHERES Registry now accelerates precision medicine research to optimize treatment efficacy and safety.

Key Points: 
  • SPHERES Registry now accelerates precision medicine research to optimize treatment efficacy and safety.
  • Targeting a cohort of over 300 SPHERES Registry participants, the biospecimen collection will include multiple treatment regimens, including relapse events.
  • "The dedication of patients and healthcare providers to make the SPHERES Registry a success is truly remarkable.
  • The SPHERES Registry includes NMO, MOGAD, and seronegative NMOSD patients.

The SPHERES Registry of Patients with NMOSD Reaches Enrollment Milestone of 200 Patients

Retrieved on: 
Wednesday, April 12, 2023
David Geffen School of Medicine at UCLA, Pros, Central nervous system, Therapy, Registry, Disability, NMO, MFIS, Spinal cord, Aes, Quality of life, Research, Brain, Biomarker, Experiment, Synergy, Disability studies, SPHERES, Patient, Physician, Collection, Cranial nerves, Neuromyelitis optica spectrum disorder, Diagnosis, UCLA, FDA, Disease, Autoimmunity, Safety, Inflammation, Pharmaceutical industry, Medicine, NMOSD

The SPHERES Registry has recruited 200 patients, across 23 sites in North America, supported by 72 physicians.

Key Points: 
  • The SPHERES Registry has recruited 200 patients, across 23 sites in North America, supported by 72 physicians.
  • Launched in early 2021, the SPHERES Registry serves as the first regulatory-grade and real-world study to advance the understanding of NMOSD.
  • To date, the SPHERES Registry has recruited 200 patients, across 23 sites in North America, supported by 72 physicians.
  • Today, advances in diagnosis, biomarkers, and newly FDA-approved treatment options offer patients with NMOSD the promise to lessen or prevent disability and enhance quality of life.

Global and Regional Next-Generation Sequencing (NGS) Informatics Market Report 2022-2032: Burgeoning Opportunities in the Evolving Regulatory Landscape for Clinical NGS - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 1, 2023
Health, Genetics, Biotechnology, Laboratory, Government, Thermo Fisher Scientific, Korea Disease Control and Prevention Agency, SPHERES, NGS, Cancer, Informatics, Patient, Region, IVDD, Research, CDC, SAML-based products and services, Conditional sentence, COVID-19, Name, Strengthening Public Health Emergency Response Act of 2015, Software, Vaccine, Medical device, Epidemiology

The global NGS informatics market was valued at $1,380.0 million in 2021 and is projected to reach $6,715.0 million by the end of 2032.

Key Points: 
  • The global NGS informatics market was valued at $1,380.0 million in 2021 and is projected to reach $6,715.0 million by the end of 2032.
  • The evolving regulatory landscape for clinical NGS and the growing number of gene mutations across various diseases are some of the major opportunities in the global NGS informatics market.
  • Application: The global NGS informatics market (by application) is expected to be dominated by the genetic screening segment.
  • End User: The global NGS informatics market (by end user) is dominated by the pharmaceutical and biotechnology companies segment.

Global and Regional Next-Generation Sequencing (NGS) Informatics Market Report 2022: A $6.71 Billion Market by the End of 2032 - Increasing Clinical Applications in Oncology to Identify Treatments

Retrieved on: 
Wednesday, February 1, 2023
Biotechnology, Laboratory, Government, Thermo Fisher Scientific, Korea Disease Control and Prevention Agency, SPHERES, NGS, Cancer, Informatics, Patient, Region, IVDD, Research, CDC, SAML-based products and services, Conditional sentence, COVID-19, Name, Strengthening Public Health Emergency Response Act of 2015, Software, Vaccine, Medical device, Epidemiology

The global NGS informatics market was valued at $1,380.0 million in 2021 and is projected to reach $6,715.0 million by the end of 2032.

Key Points: 
  • The global NGS informatics market was valued at $1,380.0 million in 2021 and is projected to reach $6,715.0 million by the end of 2032.
  • The evolving regulatory landscape for clinical NGS and the growing number of gene mutations across various diseases are some of the major opportunities in the global NGS informatics market.
  • Application: The global NGS informatics market (by application) is expected to be dominated by the genetic screening segment.
  • End User: The global NGS informatics market (by end user) is dominated by the pharmaceutical and biotechnology companies segment.